| P2093 | author name string | Chin Yu | |
| | Sepuru K Mohan | |
| | Ing-Ming Chiu | |
| | Sandhya G Rani | |
| P2860 | cites work | Cellular signaling by fibroblast growth factor receptors | Q24301087 |
| | Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination | Q26778405 |
| | 1H NMR structural characterization of a nonmitogenic, vasodilatory, ischemia-protector and neuromodulatory acidic fibroblast growth factor | Q27622574 |
| | Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate | Q27640887 |
| | Heparin structure and interactions with basic fibroblast growth factor | Q27732601 |
| | X-ray crystal structure of human acidic fibroblast growth factor | Q27732790 |
| | Structure of a heparin-linked biologically active dimer of fibroblast growth factor | Q27760195 |
| | Solution structure of acidic fibroblast growth factor bound to 1,3, 6-naphthalenetrisulfonate: a minimal model for the anti-tumoral action of suramins and suradistas | Q27765171 |
| | Tumor angiogenesis: therapeutic implications | Q27860595 |
| | HADDOCK: a protein-protein docking approach based on biochemical or biophysical information | Q27860814 |
| | Protein backbone angle restraints from searching a database for chemical shift and sequence homology | Q27861108 |
| | Fibroblast growth factors, their receptors and signaling | Q28140520 |
| | Three-Dimensional Structures of Acidic and Basic Fibroblast Growth Factors | Q28267322 |
| | 1H-NMR assignment and solution structure of human acidic fibroblast growth factor activated by inositol hexasulfate | Q28286658 |
| | Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 |
| | Angiogenesis in life, disease and medicine | Q29614539 |
| | HADDOCK versus HADDOCK: new features and performance of HADDOCK2.0 on the CAPRI targets | Q29615981 |
| | A small molecule-kinase interaction map for clinical kinase inhibitors | Q29617451 |
| | BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 |
| | Angiogenesis as a therapeutic target | Q29619525 |
| | Angiogenic factors | Q29620582 |
| | Cyclin K and cyclin D1b are oncogenic in myeloma cells. | Q33895292 |
| | Amino acid type determination in the sequential assignment procedure of uniformly 13C/15N-enriched proteins. | Q34363664 |
| | Angiogenesis and lung cancer: prognostic and therapeutic implications | Q34417759 |
| | Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration | Q34425420 |
| | Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate | Q34442255 |
| | Small-molecule inhibitors of fibroblast growth factor receptor (FGFR) tyrosine kinases (TK). | Q35061293 |
| | Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction | Q35229509 |
| | Protein kinase inhibitors: insights into drug design from structure. | Q35697409 |
| | Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity | Q35994206 |
| | Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis | Q36111400 |
| | Lessons from phase III clinical trials on anti-VEGF therapy for cancer | Q36366446 |
| | Oligomerization of acidic fibroblast growth factor is not a prerequisite for its cell proliferation activity. | Q36639272 |
| | A general enhancement scheme in heteronuclear multidimensional NMR employing pulsed field gradients | Q36732974 |
| | The FGF family: biology, pathophysiology and therapy | Q36933339 |
| | Solution NMR structure of a human FGF-1 monomer, activated by a hexasaccharide heparin-analogue. | Q38309317 |
| | Backbone dynamics of a biologically active human FGF-1 monomer, complexed to a hexasaccharide heparin-analogue, by 15N NMR relaxation methods. | Q38310289 |
| | Solution structure of the ligand binding domain of the fibroblast growth factor receptor: role of heparin in the activation of the receptor. | Q38318416 |
| | The PIP2 binding mode of the C2 domains of rabphilin-3A | Q38528805 |
| | Fibroblast growth factors, proteins with a broad spectrum of biological activities. | Q40395069 |
| | Adenovirus-mediated expression of a soluble fibroblast growth factor receptor inhibits in vitro growth of prostate DU145 cells | Q40529759 |
| | Nature of the interaction of growth factors with suramin | Q42816405 |
| | Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide | Q42824412 |
| | The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin | Q47682341 |
| | PLUSH TACSY: Homonuclear planar TACSY with two-band selective shaped pulses applied to C?,C? transfer and C?,Caromatic correlations | Q60173739 |
| | Conformation of two non-immunosuppressive FK506 analogs when bound to FKBP by isotope-filtered NMR | Q67541508 |
| | Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients | Q73029364 |
| | Transplacental carcinogenesis by stilbestrol | Q95784569 |
| | Enhanced-Sensitivity Triple-Resonance Spectroscopy with Minimal H2O Saturation | Q108784215 |
| | A Gradient-Enhanced HCCH-TOCSY Experiment for Recording Side-Chain 1H and 13C Correlations in H2O Samples of Proteins | Q110644268 |
| P921 | main subject | angiogenesis inhibitor | Q574834 |
| | sodium 2-amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoate | Q27105010 |
| P577 | publication date | 2012-06-05 | |
| P1433 | published in | Archives of Biochemistry and Biophysics | Q635818 |
| P1476 | title | WITHDRAWN: Interaction of FGF1 with a novel anti-angiogenic drug SSR128129E | |